Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock price drops attributed to alleged violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" and ignored compliance requirements, leading to poor customer experiences and higher withdrawal rates [4]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Investor Guidance - Investors affected by the stock drop are encouraged to seek legal options and can submit their information to the law firm handling the case [8].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [2][4][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic for moderate to severe hidradenitis suppurativa [5]. Allegations and Claims - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alleging that MoonLake misrepresented its clinical data and the benefits of its Nanobody structure compared to traditional monoclonal antibody treatments [4][6][7]. - The complaint suggests that the company's claims about "strong clinical data" and differentiation from competitors were misleading [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. Stock Performance - Following the announcement of the delayed launch, Inspire's stock price fell by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Allegations of Fraud - During the relevant period, James Hardie misrepresented the strength and momentum of its North American fiber cement segment, claiming sustainable customer demand when, in fact, sales were driven by inventory loading by channel partners [5]. - On August 19, 2025, the company disclosed a 12% decline in North American fiber cement sales, revealing that customers were destocking to return to normal inventory levels, which led to a stock price drop of over 34% from $28.43 to $18.64 per share [6]. Group 4: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential securities fraud related to the inflation of long-lived asset values, following significant stock price drops due to impairment charges and delayed earnings announcements [3][4][5][6]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Beyond Meat for possible violations of federal securities laws [1]. - The investigation focuses on whether Beyond Meat inflated the value of certain long-lived assets [4]. Group 2: Stock Performance - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, which was anticipated to be material, leading to a stock price drop of approximately 23%, from $2.84 to $2.185 per share [5]. - Following the announcement of a delay in the 3Q 2025 earnings report on November 3, 2025, Beyond Meat's stock experienced further significant declines during trading [6].

Core Points - A securities class action lawsuit has been filed against Synopsys, Inc. for failing to disclose material information during the class period from December 4, 2024, to September 9, 2025 [3][4] - Investors who suffered substantial losses have until December 30, 2025, to file lead plaintiff applications [1][2] Financial Performance - Synopsys reported 3Q2025 revenue of $1.740 billion, which was below the guidance range of $1.755 billion to $1.785 billion [4] - The company's net income for 3Q2025 was $242.5 million, representing a 43% decline from $425.9 million in 3Q2024 [4] - The Design IP segment contributed approximately 25% of total revenue, amounting to $426.6 million, a 7.7% year-over-year decline [4] - Guidance indicated that Design IP revenues are expected to decline by at least 5% for the full fiscal year 2025 [4] Stock Market Reaction - Following the financial results announcement, Synopsys' share price dropped by $216.59, or 35.8%, closing at $387.78 per share on September 10, 2025 [5]

Core Viewpoint - Perrigo Company plc is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its baby formula business acquired from Nestlé, which suffered from underinvestment and required significant additional expenditures to address operational issues [5]. Summary by Sections Class Action Lawsuit - The Schall Law Firm is reminding investors of a class action lawsuit against Perrigo for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Perrigo's securities between February 27, 2025, and November 4, 2025, are encouraged to contact the firm before January 16, 2026 [2]. Allegations Against Perrigo - The complaint alleges that Perrigo made false and misleading statements to the market regarding the state of its baby formula business, which required substantial investments beyond initial cost estimates to rectify its issues [5]. - The company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [5]. Legal Representation - The Schall Law Firm specializes in securities class action lawsuits and is representing investors globally [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Jayud Global Logistics Ltd. for the period between April 21, 2023, and April 30, 2025, due to alleged fraudulent activities and misleading statements by the company [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Jayud was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [5]. - Allegations include that insiders used offshore accounts to dump shares during a price inflation campaign, and that Jayud's public statements failed to disclose the false rumors and artificial trading activity affecting stock prices [5]. - The lawsuit asserts that the positive statements made by Jayud regarding its business and operations were materially misleading and lacked a reasonable basis [5]. Group 2: Participation Information - Investors who purchased Jayud securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. - A lead plaintiff must file a motion with the court by January 20, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

Accessibility StatementSkip Navigation BENSALEM, Pa., Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP) 21% more press release views with Request a Demo Also from this source IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSPIRE MEDICAL SYSTEMS, INC. (INSP), CONTACT THE LAW OFFICES OF HOWARD G. SMIT ...

Core Viewpoint - Freeport-McMoran Inc. is facing a class action lawsuit due to alleged securities fraud related to safety issues at its Grasberg Block Cave operation in Indonesia, which resulted in significant stock price declines following a tragic incident involving trapped workers [2][3][4][5][6]. Incident Overview - On September 9, 2025, Freeport announced the suspension of mining activities at the Grasberg Block Cave after a large flow of wet material trapped seven workers, leading to a stock price drop of $2.77, or 5.9%, closing at $43.89 per share [2]. - An update on September 24, 2025, revealed that two of the trapped workers had died, causing the stock price to fall by $7.69, or 17%, to close at $37.67 per share [3]. - Following media reports on September 25, 2025, regarding the implications of the production halt on Freeport's relationship with the Indonesian government, the stock price dropped another $2.33, or 6.2%, closing at $35.34 [4]. Lawsuit Details - The class action lawsuit alleges that Freeport made materially false and misleading statements and failed to disclose critical safety risks associated with its operations [5][6]. - Specific allegations include inadequate safety measures at the Grasberg mine, which heightened the risk of worker fatalities and led to undisclosed regulatory and reputational risks [6].